148870-57-9

Basic information

• Product Name: 7,8-Dimethoxy-3-(3-iodopropyl)-1,3-dihydro-2H-3-benzazepin-2-one
• Synonyms: 7,8-Dimethoxy-3-(3-iodopropyl)-1,3-dihydro-2H-3-benzazepin-2-one;3-(3-Iodopropyl)-7,8-diMethoxy-1,3-dihydro-2H-3-benzazepin-2-one;7,8-DiMethoxy-3-(3-iodopropyl)-1,3-dihydro-2H-3-benzazepin-2-on;1,3-Dihydro-3-(3-iodopropyl)-7,8-dimethoxy-2H-3-benzazepin-2-one;3-(3-iodopropyl)-7,8-diMethoxy-2,3-dihydro-1H-3-benzazepin-2-one;7,8-DiMethoxy-3-(3-iodopropyl)-1,3-dihydro-2H;3-(3-iodopropyl)-7,8-diMethoxy-1H-benzo[d]azepin-2(3H)-one;Ivabradine Impurity g
• CAS NO: 148870-57-9
• Molecular Formula: C₁₅H₁₈INO₃
• Molecular Weight: 387.21279
• EINECS: 1806241-263-5
• Mol File: 148870-57-9.mol

Chemical Properties

• Boiling Point: 504.51 °C at 760 mmHg
• Flash Point: 258.919 °C
• Appearance: /
• Density: 1.513
• Vapor Pressure: 2.64E-10mmHg at 25°C
• Refractive Index: 1.592
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: -1.23±0.20(Predicted)
• CAS DataBase Reference: 7,8-Dimethoxy-3-(3-iodopropyl)-1,3-dihydro-2H-3-benzazepin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7,8-Dimethoxy-3-(3-iodopropyl)-1,3-dihydro-2H-3-benzazepin-2-one(148870-57-9)
• EPA Substance Registry System: 7,8-Dimethoxy-3-(3-iodopropyl)-1,3-dihydro-2H-3-benzazepin-2-one(148870-57-9)

Safety Data

• Hazardous Substances Data: 148870-57-9(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
7,8-Dimethoxy-3-(3-iodopropyl)-1,3-dihydro-2H-3-benzazepin-2-one is utilized as a key intermediate in the synthesis of various pharmaceutical agents. Its unique structure allows for the development of new drugs with potential therapeutic applications, particularly in the treatment of neurological disorders and other conditions that may benefit from its chemical properties.
Used in Drug Development:
In the pharmaceutical industry, 7,8-Dimethoxy-3-(3-iodopropyl)-1,3-dihydro-2H-3-benzazepin-2-one serves as a precursor for the creation of novel drug candidates. Its chemical composition and potential interactions with biological targets make it a valuable asset in the discovery and optimization of new therapeutic agents.
Used in Neurotransmitter Research:
7,8-Dimethoxy-3-(3-iodopropyl)-1,3-dihydro-2H-3-benzazepin-2-one is employed as a research tool in studies focused on neurotransmitters. Its structure and properties may provide insights into the mechanisms of neurotransmission and contribute to the understanding of neurochemical processes.
Used in Neuropharmacology:
In neuropharmacological research, 7,8-Dimethoxy-3-(3-iodopropyl)-1,3-dihydro-2H-3-benzazepin-2-one is used to explore its potential effects on the central nervous system. Its interactions with neurotransmitter systems and other neurobiological pathways could lead to the development of new treatments for neurological and psychiatric disorders.
Further studies and research are essential to fully explore the potential uses and applications of 7,8-Dimethoxy-3-(3-iodopropyl)-1,3-dihydro-2H-3-benzazepin-2-one, as its unique properties may offer significant contributions to various scientific and medical fields.

InChI:InChI=1/C15H18INO3/c1-19-13-8-11-4-7-17(6-3-5-16)15(18)10-12(11)9-14(13)20-2/h4,7-9H,3,5-6,10H2,1-2H3

Upstream product

• 73954-34-4 N-(2,2-dimethoxy-ethyl)-3,4-dimethoxyphenylacetamide 
• 93-17-4 3,4-dimethoxyphenylacetonitrile 
• 5663-56-9 2-(3,4-dimethoxyphenyl)acetamide 
• 73942-87-7 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one 
• 85175-59-3 3-(3-chloropropyl)-1,3-dihydro-7,8-dimethoxy-2H-3-benzazepine-2-one 

Downstream Products

• 155974-00-8 ivabradine 
• 1086026-31-4 3-{3-[{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-(methyl)amino]propyl}-7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one 
• 96254-90-9 3-(3-{Allyl-[2-(3,4-dimethoxy-phenyl)-ethyl]-amino}-propyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[d]azepin-2-one 
• 85175-76-4 1-[7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-on-3-yl]-3-[N-(2-{3,4-dimethoxy-phenyl}-ethyl)-amino]-propane 

Relevant articles and documents

AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS

: Disclosed herein is an improved process for the preparation of Ivabradine and pharmaceutically acceptable salts thereof. The invention more particularly disclosesthe synthesis of key intermediates viz.,(S)-N-[(4,5-dimethoxybenzocydobut-l-yl)-methyl]-N- (methyl)amine hydrochloride of Formula-II and 3-(3-Iodopropyl)-7,8-dimethoxy-1,3-dihydro-2H-3-benzapin-2-one of Formula-III, and its use in industrial synthesis of Ivabradine and pharmaceutically acceptable salts thereof.

IVABRADINE HYDROCHLORIDE AND THE PROCESSES FOR PREPARATION THEREOF

The present disclosure relates to a process of preparing Ivabradine Hydrochloride, which is devoid of product related impurities. More specifically, the present disclosure provides a process to obtain a new polymorph of Ivabradine Hydrochloride, wherein said polymorph is pure and devoid of impurities at particular RRTs. The disclosure further relates to the removal of specific impurities of Formula 8 and/or Formula 9 during the preparation of said Ivabradine Hydrochloride. The disclosure also specifically provides the said polymorphic form of Ivabradine Hydrochloride.

PROCESS FOR PREPARATION OF IVABRADINE

A process for the preparation of ivabradine pharmaceutically acceptable salts is disclosed. An amorphous form of ivabradine hydrochloride and a process for the preparation of it are also provided.

PROCESS FOR MAKING IVABRADINE

The invention relates to an improved process for making ivabradine of formula (I) or an acid addition salt thereof, by hydrogenation of dehydroivabradine of formula (II) as well as to an improved process for making said dehydroivabradine of formula (II) or an acid addition salt thereof.

PROCESS FOR PREPARATION OF IVABRADINE

The present invention describes a new process for optical resolution of [N-[[3,4- dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]-N-methylamine] which is an intermediate in the preparation of ivabradine.

Parallel solid-phase synthesis of zatebradine analogues as potential If channel blockers

The first solid-phase synthesis of zatebradine 1 and its analogues is reported. This has resulted in the preparation of compounds with increased ability to reduce the spontaneous beating of isolated guinea-pig atria in a concentration-dependent manner. One example, 8g, showed a maximum reduction of beating of 80% at 3 μM compared to a reduction of 40% at 3 μM with zatebradine 1.

(Benzocycloalkyl) alkylamines

The compounds are 3-[ (benzocycloalkyl)alkyl amino alkyl] -1,3,4,5-te trahydro 2H- 3-benzazepin-2 ones useful in cardiovascular field.A compound disclosed is (R,S)-7,8-dimethoxy-3-{3-{N-[(4,5-dimethoxybenzocyclobut-1-yl) methyl]-N-methyl amino}propyl}-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one.